���他鲁肽药理机制 — Complete Guide

By Editorial Desk · published 2025-11-08 · last reviewed 2025-12-05 · Wiki

This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-12-05. Anything still debated is marked as such rather than presented as settled.

瑞他鲁肽药理机制

瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。

该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。

临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。

Retatrutide Background and Receptor Activity

The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.

Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.

Retatrutide at a glance

Notes from published material

Lactose, maltose and sucrose are disaccharides, also called "compound sugars". They share the formula C12H22O11. They are formed by the condensation of two monosaccharide molecules with the expulsion of a molecule of water.

=== Safety === Mild to moderate gastrointestinal side effects (such as nausea, cramping, bloating, and abdominal discomfort) are common after ESG (reported in over 70% of patients), but these are predictable, temporary, and can be managed with medications. Most will resolve within one week after ESG. Due to the minimally invasive nature of ESG, serious complications are rare. These include pain or nausea requiring hospitalization (1.08%); upper gastrointestinal tract bleeding (0.56%); peri-gastric leak or infected fluid collection (0.48%); pulmonary embolism (0.06%); perforation (0.06%). Similar rates of serious adverse events were reported in the multicenter, randomized controlled MERIT study. No deaths have been observed in the published ESG literature.

These fractions also contained toxins readily separable from the short-chain isotoxin by preparative reverse-phase chromatography. Amino-acid sequencing of the first 28 residues indicated that both toxins were long-chain neurotoxins with identical N-termini. The LD50 of long-chain neurotoxins 2 from N. a. annulata and N. christyi venoms were 0.086 and 0.090 mg/kg, respectively. The venoms of these little-known elapids have some of the lowest intraperitoneal LD50 values of any African Naja species studied thus far, and have high concentrations of potent postsynaptic neurotoxins.

Radioactive thorium was used in the 1950s and 60s to treat tuberculosis and other benign diseases (including children), with serious consequences (see Peteosthor). A stabilized suspension of colloidal thorium(IV) oxide, co-developed by António Egas Moniz (1874-1954), was used from 1929 under the trade name Thorotrast as an X-ray contrast agent for angiography in several million patients worldwide until it was banned in the mid-1950s. It accumulates in the reticulohistiocytic system and can lead to cancer due to locally increased radiation exposure. The same is true for cholangiocarcinoma and angiosarcoma of the liver, two rare liver cancers. Carcinomas of the paranasal sinuses have also been described following administration of Thorotrast. Typical onset of disease is 30–35 years after exposure. The biological half-life of Thorotrast is approximately 400 years. The largest study in this area was conducted in Germany in 2004 and showed a particularly high mortality rate among patients exposed in this way. The median life expectancy over a seventy-year observation period was 14 years shorter than in the comparison group.

Sources: en.wikipedia.org

Related pages on this site

• Durable index
• Scalable comparison
• Clear collection
• Lightweight overview
• Portable checklist
• Tracked digest
• Optimized checklist
• Modern analysis

Background from the literature

To promote weight gain and muscle growth As an adjunct in the treatment of bone pain and decreased bone strength associated with osteoporosis As an adjunct for catabolic states such as corticosteroid therapy and convalescence as in chronic infections, extensive surgery, and severe trauma To treat treatment-refractory anemias (via stimulation of erythropoiesis) such as acquired and congenital aplastic anemia and anemia of chronic kidney disease As an adjunct to improve strength and well-being in arthritis To treat short stature in youth

== Further reading == Kleerebezem M, Boekhorst J, van Kranenburg R, et al. (February 2003). "Complete genome sequence of Lactobacillus plantarum WCFS1". Proceedings of the National Academy of Sciences of the United States of America. 100 (4): 1990–1995. Bibcode:2003PNAS..100.1990K. doi:10.1073/pnas.0337704100. JSTOR 3138472. PMC 149946. PMID 12566566.

== History == After the sale of KFC in 1964, Lee Cummings (the nephew of KFC founder Colonel Harland Sanders) began developing his recipe, later to be known as "Famous Recipe." In 1966, Cummings, along with Harold Omer, started "Harold's Take-Home" in Lima, Ohio, where Cummings first introduced his Famous Recipe Chicken. Later that year, Cummings opened the restaurant's first franchise in Columbus, Ohio. Locations in Springfield, Dayton, and Cincinnati, Ohio, followed in the coming years, as well as a unit in Kalamazoo, Michigan. In 1981, Cummings sold the chain to Shoney's Restaurants in Nashville, Tennessee. He died in 2002 at the age of 80. Shoney's continued to operate Lee's along with their own Captain D's and Shoney's Restaurants until 1995, when Lee's was sold to RTM Restaurant Group in Atlanta, Georgia. In May 2003, the chain had 29 company-owned locations and 125 franchised locations. In October 2003, Lee's Famous Recipes Inc. purchased the chain from RTM. In April 2013, Famous Recipe Group LLC purchased the chain from Lee's Famous Recipes, Inc. In June 2021, Famous Recipe Group, LLC, brand owner of Lee's Famous Recipe Chicken, agreed to sell the brand to LFR Chicken, LLC a new entity backed by Artemis Lane Partners.

Sources: en.wikipedia.org

Frequently asked questions